# US 2021/0340613 A1 · Sequencing methods and compositions for prenatal diagnoses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340613 A1
- Document ID: US20210340613A1
- Status: Published application
- Kind: A1
- Application number: 17/193,279
- Filed: 2021-03-05
- Published: 2021-11-04
- Earliest claimed: 2010-01-19
- Assignees: Verinata Health, Inc.
- Applicants: Verinata Health, Inc.
- Inventors: Richard P. Rava; Manjula Chinnappa; David A. Comstock; Gabrielle Heilek; Brian Kent Rhees
- Web page: https://patentgrep.com/patent/US20210340613A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- G16B 20/10: Ploidy or copy number detection
- G16B 30/10: Sequence alignment; Homology search
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.

## Claims

### Claim 1

A method for determining a fetal chromosomal aneuploidy in a maternal sample comprising a mixture of fetal and maternal nucleic acids molecules, said method comprising:
(a) preparing a sequencing library from said mixture of fetal and maternal nucleic acid molecules; wherein preparing said library comprises the consecutive steps of end-repairing, dA-tailing and adaptor ligating said nucleic acids;
(b) sequencing at least a portion of said nucleic acid molecules, thereby obtaining sequence information for a plurality of fetal and maternal nucleic acid molecules of a maternal sample;
(c) using the sequence information to obtain a chromosome dose for an aneuploid chromosome; and
(d) comparing said chromosome dose to at least one threshold value, and thereby identifying the presence or absence of fetal aneuploidy

### Claim at position 2

2-43. (canceled)

### Claim 44

A method for preparing a sequencing library from a test sample comprising nucleic acid molecules, wherein said nucleic acids are human cell-free DNA (cfDNA) molecules, wherein the method comprises the consecutive steps of end-repairing, dA-tailing and adaptor ligating said nucleic acids, wherein said consecutive steps exclude purifying the end-repaired products prior to the dA-tailing step and exclude purifying the dA-tailing products prior to the adaptor-ligating step, and wherein said consecutive steps are performed in less than 1 hour.

### Claim 45 (depends on 44)

The method of claim 44, wherein said consecutive steps are performed in the absence of polyethylene glycol.

### Claim 46 (depends on 44)

The method of claim 44, wherein said nucleic acids are not subjected to fragmentation prior to the consecutive steps of end-repairing, dA-tailing and adaptor ligating said nucleic acids.

### Claim 47 (depends on 44)

Use of a sequencing library prepared according to the method of claim 44 in a nucleic acid sequencing method.

### Claim 48 (depends on 47)

The use of claim 47, wherein said sequencing method is a next generation sequencing (NGS) method.

### Claim 49 (depends on 47)

The use of claim 47, wherein said sequencing method is a massively parallel sequencing method, and wherein optionally:
(i) said sequencing is massively parallel sequencing using sequencing-by-synthesis with reversible dye terminators; or
(ii) said sequencing is massively parallel sequencing using sequencing-by-ligation.

### Claim 50 (depends on 47)

The use of claim 47, wherein said sequencing comprises an amplification.

### Claim 51 (depends on 47)

The use of claim 47, wherein said sequencing is single molecule sequencing.

### Claim 52 (depends on 44)

The method of claim 44, wherein the sample is a plasma sample derived from peripheral blood that comprises a mixture of cfDNA derived from normal and cancerous cells.
